摘要
目的评价替格瑞洛在急性冠脉综合征(ACS)患者PCI术中的临床应用效果。方法入选ACS并行PCI治疗的患者76例,随机分为氯吡格雷组、替格瑞洛组,每组38例,比较两组治疗效果。结果入组后30 d内,两组的心血管事件和副作用发生情况比较,差异无统计学意义(P>0.05)。随访1个月,替格瑞洛组ADP诱导的血小板聚集抑制率为(58.4±14.7)%,氯吡格雷组为(56.8±14.9)%,其中,氯吡格雷组有3例患者ADP诱导的血小板聚集抑制率<30%,存在氯吡格雷抵抗。结论相较于氯吡格雷,替格瑞洛可以提高ADP诱导的血小板聚集抑制率,保证ACS患者PCI抗栓指标合格。
Objective To evaluate the clinical effect of ticagrelor in the treatment of patients with acute coronary syndrome （ACS） undergoing PCI. Methods A total of 76 cases of ACS patients who needed PCI were selected and randomly divided into ticagrelor group and clopidogrel group, the therapeutic effects of the two groups were compared. Results Within 30 days after admission, there was no significant difference in incidence of cardiovascular and adverse events （P〈0.05）.The patients were followed up for 1 months, ADP induced platelet aggregation inhibition rate in the ticagrelor group was （56.8±14.9）%, while that in the elopidogrel group was （58.4±14.7）%. In clopidogrel group, there were 3 patients had ADP induced platelet aggregation inhibition rate 〈30%, and it showed clopidogrel resistance. Conclusion Compared with clopidogrel, ticagrelor can effectively improve the ADP induced platelet aggregation inhibition rate, and ensure the antithrombotic standard in patients with acute coronary syndrome after PCI.
出处
《临床医学研究与实践》
2017年第28期3-5,共3页
Clinical Research and Practice
